



## WHAT IS VIRCAN?

**VIRCAN** is a structured academic-community partnership that will address issues throughout the care of viral hepatitis, *from diagnosis to treatment to cure.*

Based out of the Toronto Centre for Liver Disease (TCLD), one of the largest liver units in North America, the VIRCAN team looks forward to demonstrating how viral hepatitis screening and treatment should be optimized in other urban settings across Canada, and around the world.

## LOCATIONS



### 1. TORONTO CENTRE FOR LIVER DISEASE

Toronto General Hospital  
200 Elizabeth Street  
Toronto, ON M5G 2C4  
T. 416 340 4186  
F. 416 340 4819

### 2. ETOBICOKE LIVER CLINIC

817 Brown's Line  
Toronto, ON M8W 3V7  
(Brown's Line & Evans Ave.)  
T. 416 503 2626  
F. 416 503 2665

### 3. RICHMOND HILL LIVER CLINIC

328 Highway 7 E., Suite 301  
Richmond Hill, ON L4B 3P7  
(Bayview Ave. & Hwy 7)  
T. 905 771 8821  
F. 905 771 8481

### 4. SCARBOROUGH LIVER CLINIC

3030 Lawrence Ave E., Suite 510  
Toronto, ON M1P 2T7  
(McCowan Rd. & Lawrence Ave. E)  
T. 416 431 4402  
F. 416 431 0762

### 5. TORONTO MIDTOWN LIVER CLINIC

187 St. Clair Ave W., Suite 1  
Toronto, ON M4V 1P7  
(Avenue Rd. & St. Clair Ave W.)  
T. 416 922 6022  
F. 416 922 9100

## VIRCAN CLINICS ARE:



### COMPREHENSIVE IN CARE

1 to 1 service, health education and promotion in communities across the GTA



### ACCESSIBLE

Eliminates systemic barriers to full participation



### CLIENT AND COMMUNITY FOCUSED

The needs of those groups and individuals are of primary importance



### INTEGRATING SERVICES

VIRCAN Clinics will have strong connections with health system and community partners




### MULTIDISCIPLINARY APPROACH

VIRCAN team will work in collaborative practice to address the health needs of their clients

## THE TORONTO VIRAL HEPATITIS CARE NETWORK


Transforming the care  
of Viral Hepatitis



**VIRCAN.CA**

## VIRAL HEPATITIS

Viral hepatitis is an emerging global epidemic and accounts for significant health and economic burden. In Canada, Hepatitis B (HBV) and Hepatitis C (HCV) are, by years lost, the most harmful infectious diseases. Yet this public threat is silent: most people do not know they are infected and may not show signs of liver damage for years.



ESTIMATED NUMBER OF YEARS OF LIFE LOST (YLL) DUE TO PREMATURE MORTALITY<sup>1</sup>.

## THE TORONTO VIRAL HEPATITIS CARE NETWORK

Officially launched on August 1st 2016, **VIRCAN** will transform the care of viral hepatitis by systematically addressing and eliminating barriers to diagnosis and treatment, providing everyone access to effective and high quality care.

## THE VIRCAN TEAM

**VIRCAN** are global leaders in hepatology dedicated to patient care and public health.



### VIRCAN EXECUTIVE DIRECTOR:

Dr. Harry Janssen, MD, PhD is the Francis Family Chair in Liver Research and the Director of the Toronto Centre for Liver Disease – the largest clinical program in liver disease and viral hepatitis in North America.

### SCIENTIFIC DIRECTOR:

Jordan Feld, MD, MPH, FRCP (C)

### EDUCATION DIRECTOR:

Hemant Shah, MD, MScCH HPTE

### MEDICAL DIRECTOR:

Joshua Juan, BSc., MD, CCFP (Hepatology)

### CLINICAL HEPATOLOGIST:

Karli Moncrief, MD MSc FRCPC

### MANAGING DIRECTOR:

Camelia Capraru

### COMMUNITY OUTREACH & ENGAGEMENT SPECIALIST:


Vivien Chung, MSW, RSW

## VIRCAN CLINICS

Adopting a ‘hub-and-spoke’ model, **VIRCAN** supports a network of community-based treatment centres across GTA.

**VIRCAN** Clinics will offer point-of-care testing for HBV and HCV, non-invasive fibrosis assessment (Fibroscan®) at no cost to patients, providing the best and most current evidence-based treatments in Hepatology.

### HOW GENERAL PRACTITIONERS CAN HELP:



Made possible through the support of Gilead Sciences Inc., AbbVie, Merck Canada Inc. and OraSure Technologies Inc./KNS Canada Inc. The opinions expressed in this material are those of the authors and do not necessarily reflect the views of the Sponsors.

References: 1. Kwong JC, Ratnasingham S, Campitelli MA, et al. The impact of infection on population health: results of the Ontario burden of infectious disease study. PLoS ONE 2012;7:e44103.